ES2181915T3 - Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. - Google Patents

Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.

Info

Publication number
ES2181915T3
ES2181915T3 ES96936385T ES96936385T ES2181915T3 ES 2181915 T3 ES2181915 T3 ES 2181915T3 ES 96936385 T ES96936385 T ES 96936385T ES 96936385 T ES96936385 T ES 96936385T ES 2181915 T3 ES2181915 T3 ES 2181915T3
Authority
ES
Spain
Prior art keywords
ctla
combination
csf
treat infections
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96936385T
Other languages
English (en)
Inventor
Jacques Banchereau
Odille Djossou
Leopoldo Flores-Romo
Francois Fossiez
Pierre Golstein
Mala Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Sharp and Dohme LLC
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Schering Corp filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2181915T3 publication Critical patent/ES2181915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

COMPOSICIONES Y METODOS PARA USAR CTLA-8 Y TRATAR TRASTORNOS FISIOLOGICOS EN UN INDIVIDUO. LOS METODOS COMPRENDEN LA ADMINISTRACION DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE CTLA-8 EN MONOTERAPIA O COMBINACION CON OTROS AGENTES TERAPEUTICOS; O UN ANTAGONISTA DEL CTLA-8
ES96936385T 1995-10-27 1996-10-23 Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. Expired - Lifetime ES2181915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US590995P 1995-10-27 1995-10-27
US56974295A 1995-12-08 1995-12-08

Publications (1)

Publication Number Publication Date
ES2181915T3 true ES2181915T3 (es) 2003-03-01

Family

ID=26674918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96936385T Expired - Lifetime ES2181915T3 (es) 1995-10-27 1996-10-23 Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.

Country Status (10)

Country Link
EP (1) EP0862454B1 (es)
JP (2) JP3253633B2 (es)
AT (1) ATE222768T1 (es)
AU (1) AU7439996A (es)
CA (1) CA2235951C (es)
DE (1) DE69623316T2 (es)
DK (1) DK0862454T3 (es)
ES (1) ES2181915T3 (es)
PT (1) PT862454E (es)
WO (1) WO1997015320A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2007106769A2 (en) 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
US20100310502A1 (en) * 2009-06-09 2010-12-09 Anders Linden Method of treating local infections in mammals
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
JP3501801B2 (ja) * 1990-08-23 2004-03-02 カイロン コーポレイション 組み換えコロニー刺激因子―１の使用
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
WO1995016458A1 (en) * 1993-12-13 1995-06-22 Sandoz Ltd. Il-6 therapy

Also Published As

Publication number Publication date
AU7439996A (en) 1997-05-15
EP0862454B1 (en) 2002-08-28
DK0862454T3 (da) 2002-12-30
JPH10512293A (ja) 1998-11-24
DE69623316D1 (de) 2002-10-02
JP2002145799A (ja) 2002-05-22
ATE222768T1 (de) 2002-09-15
DE69623316T2 (de) 2003-04-17
CA2235951C (en) 2003-04-01
WO1997015320A1 (en) 1997-05-01
EP0862454A1 (en) 1998-09-09
CA2235951A1 (en) 1997-05-01
JP3253633B2 (ja) 2002-02-04
HK1015692A1 (en) 1999-10-22
PT862454E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
CL2003002785A1 (es) Uso de 4,5,6,7-tetrahidroisoxazolo(5,4-c)piridin-3-ol (thip) para preparar una composicion farmaceutica util para tratar un trastorno del sueno.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
MY119403A (en) Novel compounds with analgesic effect.
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
GEP20063799B (en) Tropane derivatives useful in therapy
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
DE69230140D1 (de) Antivirale nucleosidkombination
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
BR0115162A (pt) Tratamentos antitumorais eficazes
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
ATE26216T1 (de) Zusammensetzungen mit gehalt an interferon und ihre therapeutische anwendung.
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ITMI912509A0 (it) Uso della nimesulide nel trattamento della cataratta
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES2059058T3 (es) Combinacion sinergica para uso oftalmico.
IT8319600A0 (it) Composizioni farmaceutiche e loro uso nel trattamento del glaucoma.
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
DK374584D0 (da) Analgetikum